AUG 11, 2026 · JOURNAL ARTICLE
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
Nature Medicine
Mechanistic analysis of acquired resistance in a Phase 1/2 trial, identifying actionable pathways and guiding rational combination strategies, but requiring confirmatory evidence from the ongoing Phase 3 trial.
Reported
Patients with RAS pathway alterat…26 of 44 (59%)
Patients with mutant KRAS amplifi…16 of 44 (36%)
Patients with RTK pathway alterat…4 of 44 (9%)